Crestor® now indicated to slow the progression of atherosclerosis in patients with elevated cholesterol
AstraZeneca announced today that the U.S. Food and Drug Administration (FDA) has approved CRESTOR® (rosuvastatin calcium) as an adjunct to diet to slow the progression of atherosclerosis in patients with elevated cholesterol. This new indication gives CRESTOR an important differentiator from competitors in the cholesterol-lowering marketplace.“This new indication allows us to share what we have learned in clinical trials - that even in people with low Framingham risk score, and early signs of atherosclerosis, the disease progresses if untreated,” said Mike Tilton, AstraZeneca’s Vice
